Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2011; 105(02): 381-385
DOI: 10.1160/TH10-06-0417
DOI: 10.1160/TH10-06-0417
Letters to the Editor
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies
Financial support: F.P. and R.D.C. were supported by Italian Ministry of University and Research (PRIN 2007, N°2007T9HTFB and FIRST EX-60% 2006) and by Italo Monzino Foundation.
Further Information
Publication History
Received:
29 June 2010
Accepted after major revision:
30 October 2010
Publication Date:
25 November 2017 (online)
-
References
- 1 Peyvandi F, Palla R, Lotta LA. et al. ADAMTS-13 as-says in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631-40.
- 2 Studt JD, Hovinga JA, Antoine G. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544.
- 3 Zhou Z, Han H, Cruz MA. et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease. Thromb Haemost 2009; 101: 1070-1077.
- 4 Meyer SC, Sulzer I, Lämmle B. et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-867.
- 5 Eckmann CM, De Laaf RT, Van Keulen JM. et al. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1331.
- 6 Raife TJ, Cao W, Atkinson BS. et al. Leukocyte pro-teases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-1674.
- 7 Feys HB, Vandeputte N, Palla R. et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 2053-2062.
- 8 Studt JD, Böhm M, Budde U. et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-1887.
- 9 Tripodi A, Chantarangkul V, Böhm M. et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609.
- 10 Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-1148.
- 11 Tripodi A, Peyvandi F, Chantarangkul V. et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-1541.
- 12 Peyvandi F, Lavoretano S, Palla R. et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
- 13 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
- 14 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
- 15 Mannucci PM, Peyvandi F. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). In: Postgraduate Haematology. Blackwell Publishing Ltd; 2005. pp. 876-884.
- 16 Kato S, Matsumoto M, Matsuyama T. et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
- 17 Shelat SG, Smith P, Ai J. et al. Inhibitory autoanti-bodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4: 1707-1717.
- 18 Starke R, Machin S, Scully M. et al. The clinical utility of ADAMTS13 activity, antigen and autoanti-body assays in thrombotic thrombocytopenic purpura. Br J Haematol 2006; 136: 649-655.
- 19 Kremer Hovinga JA, Vesely SK, Terrell DR. et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
- 20 Feige MJ, Simpson ER, Herold EM. et al. Dissecting the alternatively folded state of the antibody Fab fragment. J Mol Biol 2010; 399: 719-730.